Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Operating Expenses (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Operating Expenses over the past 9 years, most recently at $10.1 million for Q4 2023.

  • For Q4 2023, Operating Expenses fell 6.42% year-over-year to $10.1 million; the TTM value through Dec 2023 reached $45.1 million, up 13.16%, while the annual FY2024 figure was $48.7 million, 8.08% up from the prior year.
  • Operating Expenses for Q4 2023 was $10.1 million at Corbus Pharmaceuticals Holdings, up from $9.5 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $38.4 million in Q2 2020 and troughed at $8.2 million in Q3 2022.
  • A 5-year average of $19.1 million and a median of $16.4 million in 2021 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 121.67% in 2019 and later crashed 60.31% in 2021.
  • Year by year, Operating Expenses stood at $29.8 million in 2019, then dropped by 27.86% to $21.5 million in 2020, then crashed by 53.43% to $10.0 million in 2021, then grew by 7.99% to $10.8 million in 2022, then decreased by 6.42% to $10.1 million in 2023.
  • Business Quant data shows Operating Expenses for CRBP at $10.1 million in Q4 2023, $9.5 million in Q3 2023, and $8.2 million in Q2 2023.